These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

234 related items for PubMed ID: 20306129

  • 1. Cognitive function after adjuvant treatment for early breast cancer: a population-based longitudinal study.
    Debess J, Riis JØ, Engebjerg MC, Ewertz M.
    Breast Cancer Res Treat; 2010 May; 121(1):91-100. PubMed ID: 20306129
    [Abstract] [Full Text] [Related]

  • 2. Neurocognitive performance in breast cancer survivors exposed to adjuvant chemotherapy and tamoxifen.
    Castellon SA, Ganz PA, Bower JE, Petersen L, Abraham L, Greendale GA.
    J Clin Exp Neuropsychol; 2004 Oct; 26(7):955-69. PubMed ID: 15742545
    [Abstract] [Full Text] [Related]

  • 3. Cognitive function and quality of life after surgery for early breast cancer in North Jutland, Denmark.
    Debess J, Riis JØ, Pedersen L, Ewertz M.
    Acta Oncol; 2009 Oct; 48(4):532-40. PubMed ID: 19096948
    [Abstract] [Full Text] [Related]

  • 4. Prospective study of long-term impact of adjuvant high-dose and conventional-dose chemotherapy on health-related quality of life.
    Buijs C, Rodenhuis S, Seynaeve CM, van Hoesel QG, van der Wall E, Smit WJ, Nooij MA, Voest E, Hupperets P, TenVergert EM, van Tinteren H, Willemse PH, Mourits MJ, Aaronson NK, Post WJ, de Vries EG.
    J Clin Oncol; 2007 Dec 01; 25(34):5403-9. PubMed ID: 18048822
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Polychemotherapy for early breast cancer: results from the international adjuvant breast cancer chemotherapy randomized trial.
    Adjuvant Breast Cancer Trials Collaborative Group.
    J Natl Cancer Inst; 2007 Apr 04; 99(7):506-15. PubMed ID: 17405995
    [Abstract] [Full Text] [Related]

  • 7. Long-term cardiac follow-up in relapse-free patients after six courses of fluorouracil, epirubicin, and cyclophosphamide, with either 50 or 100 mg of epirubicin, as adjuvant therapy for node-positive breast cancer: French adjuvant study group.
    Bonneterre J, Roché H, Kerbrat P, Fumoleau P, Goudier MJ, Fargeot P, Montcuquet P, Clavère P, Barats JC, Monnier A, Veyret C, Datchary J, Van Praagh I, Chapelle-Marcillac I.
    J Clin Oncol; 2004 Aug 01; 22(15):3070-9. PubMed ID: 15284257
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Quality of life in women with breast cancer during the first year after random assignment to adjuvant treatment with marrow-supported high-dose chemotherapy with cyclophosphamide, thiotepa, and carboplatin or tailored therapy with Fluorouracil, epirubicin, and cyclophosphamide: Scandinavian Breast Group Study 9401.
    Brandberg Y, Michelson H, Nilsson B, Bolund C, Erikstein B, Hietanen P, Kaasa S, Nilsson J, Wiklund T, Wilking N, Bergh J, Scandinavian Breast Group Study 9401.
    J Clin Oncol; 2003 Oct 01; 21(19):3659-64. PubMed ID: 14512398
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Epirubicin increases long-term survival in adjuvant chemotherapy of patients with poor-prognosis, node-positive, early breast cancer: 10-year follow-up results of the French Adjuvant Study Group 05 randomized trial.
    Bonneterre J, Roché H, Kerbrat P, Brémond A, Fumoleau P, Namer M, Goudier MJ, Schraub S, Fargeot P, Chapelle-Marcillac I.
    J Clin Oncol; 2005 Apr 20; 23(12):2686-93. PubMed ID: 15837983
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Randomized trial comparing cyclophosphamide, methotrexate, and 5-fluorouracil (CMF) with rotational CMF, epirubicin and vincristine as primary chemotherapy in operable breast carcinoma.
    Cocconi G, Di Blasio B, Boni C, Bisagni G, Ceci G, Rondini E, Bella M, Leonardi F, Savoldi L, Camisa R, Bruzzi P.
    Cancer; 2002 Jul 15; 95(2):228-35. PubMed ID: 12124820
    [Abstract] [Full Text] [Related]

  • 17. Dissemination of adjuvant multiagent chemotherapy and tamoxifen for breast cancer in the United States using estrogen receptor information: 1975-1999.
    Mariotto AB, Feuer EJ, Harlan LC, Abrams J.
    J Natl Cancer Inst Monogr; 2006 Jul 15; (36):7-15. PubMed ID: 17032888
    [Abstract] [Full Text] [Related]

  • 18. Acute and late toxicity following adjuvant high-dose chemotherapy for high-risk primary operable breast cancer--a quality assessment study.
    Svane IM, Homburg KM, Kamby C, Nielsen DL, Roer O, Sliffsgaard D, Johnsen HE, Hansen SW.
    Acta Oncol; 2002 Jul 15; 41(7-8):675-83. PubMed ID: 14651213
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.